The Boston keratoprosthesis type 1 can produce significant visual recovery in eyes with debilitating corneal surface disease, but the amount of recovery may be associated with type of pathology, according to a study.In a multicenter, prospective study …
An intravitreal dexamethasone implant (Ozurdex, Allergan) can prompt improvement in patients with diabetic macular edema refractory to multiple anti-vascular endothelial growth factor (anti-VEGF) injections, according to Korean researchers. Reuters H…
Ocular Therapeutix reported a net loss of $39.7 million, or $1.71 per share, in 2015 compared with $28.7 million, or $2.69 per share, in 2014, according to a press release. Research and development expenses were reported at $26.6 million in 2015 compared with $18.9 million in 2014. The increase was attributed to personnel costs and clinical trials of Dextenza (sustained-release dexamethasone) and OTX-TP (sustained-release travoprost) product candidates, as well as preclinical development of the company’s anti-VEGF and tyrosine kinase inhibitor programs for the treatment of wet AMD and other back of the eye diseases, the release said.
(MedPage Today) — Position paper insists pharma reveal R&D costs, and more
Are intravitreal dexamethasone implants a safe and effective treatment option for diabetic macular edema? New data from real-life experience sheds some light. Eye
Quantel Medical has been awarded a €3 million competitive tender to supply ophthalmic laser equipment to military hospitals across India, according to a company press release. Under the terms of the agreement signed by the Directorate General of Armed Forces Medical Services of the Indian Ministry of Defense, Quantel will provide sixty-one 532-nm Supra with Suprascan photocoagulation lasers for use in 53 military hospitals across India.